ArticleJournal of cosmetic dermatology2022
Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
Article in Journal of cosmetic dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Alopecia areata following COVID-19 vaccine: a systematic review.European journal of medical research · 2024Pooled it
- Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Serious Adverse Events Following COVID-19 Vaccination: A Descriptive Case Series From a Rural Healthcare System.Cureus · 2026Article
- Papuloerythroderma of Ofuji Associated with Elevated Varicella-zoster Virus Complement-fixing Antibody Titers Following BNT162b2 mRNA COVID-19 Vaccination.Acta dermato-venereologica · 2025Article
- Exploring cutaneous lymphoproliferative disorders in the wake of COVID-19 vaccination.Skin health and disease · 2024Article
- Article
- Superbugs or multidrug resistant microbes: A new threat to the society.Health science reports · 2023Article
- Lichen planus after COVID-19 infection and vaccination.Archives of dermatological research · 2023Review
- Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19.Tropical medicine and infectious disease · 2023Article
- The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.Advances in experimental medicine and biology · 2023Article
- Delayed nonlocal cutaneous reactions after inactive COVID-19 vaccinations.Journal of cosmetic dermatology · 2022Article
- Cutaneous Adverse Reactions to SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis.Vaccines · 2022Review
- Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.Journal of cosmetic dermatology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
21 authors at 18 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn this study covering all of Turkey, we aimed to define cutaneous and systemic adverse reactions in our patient population after COVID-19 vaccination with the Sinovac/CoronaVac (inactivated SARS-CoV-2) and Pfizer/BioNTech (BNT162b2) vaccines.
methodsThis prospective, cross-sectional study included individuals presenting to the dermatology or emergency outpatient clinics of a total of 19 centers after having been vaccinated with the COVID-19 vaccines. Systemic, local injection site, and non-local cutaneous reactions after vaccination were identified, and their rates were determined.
resultsOf the 2290 individuals vaccinated between April 15 and July 15, 2021, 2097 (91.6%) received the CoronaVac vaccine and 183 (8%) BioNTech. Systemic reactions were observed at a rate of 31.0% after the first CoronaVac dose, 31.1% after the second CoronaVac dose, 46.4% after the first BioNTech dose, and 46.2% after the second BioNTech dose. Local injection site reactions were detected at a rate of 35.6% after the first CoronaVac dose, 35.7% after the second CoronaVac dose, 86.9% after the first BioNTech dose, and 94.1% after the second BioNTech dose. A total of 133 non-local cutaneous reactions were identified after the CoronaVac vaccine (2.9% after the first dose and 3.5% after the second dose), with the most common being urticaria/angioedema, pityriasis rosea, herpes zoster, and maculopapular rash. After BioNTech, 39 non-local cutaneous reactions were observed to have developed (24.8% after the first dose and 5% after the second dose), and the most common were herpes zoster, delayed large local reaction, pityriasis rosea, and urticaria/angioedema in order of frequency. Existing autoimmune diseases were triggered in 2.1% of the patients vaccinated with CoronaVac and 8.2% of those vaccinated with BioNTech.
conclusionsThere are no comprehensive data on cutaneous adverse reactions specific to the CoronaVac vaccine. We determined the frequency of adverse reactions from the dermatologist's point of view after CoronaVac and BioNTech vaccination and identified a wide spectrum of non-local cutaneous reactions. Our data show that CoronaVac is associated with less harmful reactions while BioNTech may result in more serious reactions, such as herpes zoster, anaphylaxis, and triggering of autoimmunity. However, most of these reactions were self-limiting or required little therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.